Disordered aldosterone-volume relationship in end-stage kidney disease

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 10, Issue 4, 2009, Pages 230-236

  Bomback, Andrew S ^a   Kshirsagar, Abhijit V ^b   Ferris, Maria E ^b   Klemmer, Philip J ^b  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Aldosterone; Chronic kidney disease; Extracellular volume; Haemodialysis; Mineralocorticoid receptor blockers

Indexed keywords

ALDOSTERONE; C REACTIVE PROTEIN; POTASSIUM;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BODY WATER; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR SPACE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYDRATION; KIDNEY FAILURE; POTASSIUM BLOOD LEVEL; PROTEIN BLOOD LEVEL; SALT INTAKE; SALT LOADING; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ALDOSTERONE; C-REACTIVE PROTEIN; CHILD; ELECTRIC IMPEDANCE; EXTRACELLULAR SPACE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POTASSIUM; RENAL DIALYSIS; SODIUM, DIETARY; WATER-ELECTROLYTE IMBALANCE;

EID: 73349089382     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/1470320309352353     Document Type: Article

References (44)

1. De Lorenzo A., Andreoli A., Matthie J., Withers P. Predicting body cell mass with bioimpedance by using theoretical methods: a technological review. J Appl Physiol 1997 ; 82: 1542-1558.
2. Levin NW, Zhu F., Seibert E., Ronco C., Kuhlmann MK Use of segmental multifrequency bioimpedance spectroscopy in hemodialysis. Contrib Nephrol 2005 ; 149: 162-167.
3. Zhu F., Wystrychowski G., Kitzler T., Thijssen S., Kotanko P., Levin NW Application of bioimpedance techniques to peritoneal dialysis. Contrib Nephrol 2006 ; 150: 119-128.
4. Kotanko P., Levin NW, Zhu F. Current state of bioimpedance technologies in dialysis. Nephrol Dial Transplant 2008 ; 23: 808-812.
5. Kuhlmann MK, Zhu F., Seibert E., Levin NW Bioimpedance, dry weight and blood pressure control: new methods and consequences. Curr Opin Nephrol Hypertens 2005 ; 14: 543-549.
6. Wabel P., Chamney P., Moissl U., Jirka T. Importance of whole-body bioimpedance spectroscopy for the management of fluid balance. Blood Purif 2009 ; 27: 75-80.
7. Tattersall J. Bioimpedance analysis in dialysis: state of the art and what we can expect. Blood Purif 2009 ; 27: 70-74.
8. Brunner HR, Laragh JH, Baer L. et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972 ; 286: 441-449.
9. Klemmer PJ, Bomback AS Extracellular volume and aldosterone interaction in chronic kidney disease. Blood Purif 2009 ; 27: 92-98.
10. Cole KS, Cole RH Dispersion and absorption in dielectrics. I: Alternating current characteristics. J Chem Phys 1941 ; 9: 341-351.
11. Piccoli A., Pastori G., Guizzo M., Rebeschini M., Naso A., Cascone C. Equivalence of information from single versus multiple frequency bioimpedance vector analysis in hemodialysis. Kidney Int 2005 ; 67: 301-313.
12. Titze J., Shakibaei M., Schafflhuber M. et al. Glycosaminoglycan polymerization may enable osmotically inactive Na+ storage in the skin. Am J Physiol Heart Circ Physiol 2004 ; 287: H203-08.
13. Titze J., Lang R., Ilies C. et al. Osmotically inactive skin Na+ storage in rats. Am J Physiol Renal Physiol 2003 ; 285: F1108-17.
14. Titze J., Maillet A., Lang R. et al. Long-term sodium balance in humans in a terrestrial space station simulation study. Am J Kidney Dis 2002 ; 40: 508-516.
15. U.S. Renal Data System, USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2006.
16. Ritz E., Wanner C. The challenge of sudden death in dialysis patients. Clin J Am Soc Nephrol 2008 ; 3: 920-929.
17. Go AS, Chertow GM, Fan D., McCulloch CE, Hsu CY Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004 ; 351: 1296-1305.
18. Pitt B., Zannad F., Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 ; 341: 709-717.
19. Pitt B., Remme W., Zannad F. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 ; 348: 1309-1321.
20. Weber KT Aldosterone in congestive heart failure. N Engl J Med 2001 ; 345: 1689-1697.
21. Brown NJ Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 2005 ; 14: 235-241.
22. Sato A., Saruta T. Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004 ; 27: 303-310.
23. Funder JW, Carey RM, Fardella C. et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008 ; 93: 3266-3281.
24. Struthers AD Aldosterone-induced vasculopathy. Mol Cell Endocrinol 2004 ; 217: 239-241.
25. Struthers AD Aldosterone in heart failure: pathophysiology and treatment. Curr Heart Fail Rep 2004 ; 1: 171-175.
26. Wizemann V., Wabel P., Chamney P. et al. The mortality risk of overhydration in haemodialysis patients. Nephrol Dial Transplant 2009 ; 24: 1574-1579.
27. Charra B., Calemard E., Ruffet M. et al. Survival as an index of adequacy of dialysis. Kidney Int 1992 ; 41: 1286-1291.
28. Charra B., Chazot C. Volume control, blood pressure and cardiovascular function. Lessons from hemodialysis treatment. Nephron Physiol 2003 ; 93: 94-101.
29. Agarwal R., Alborzi P., Satyan S., Light RP Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 2009 ; 53: 500-507.
30. Cooke CR, Horvath JS, Moore MA, Bledsoe T., Walker WG Modulation of plasma aldosterone concentration by plasma potassium in anephric man in the absence of a change in potassium balance. J Clin Invest 1973 ; 52: 3028-3032.
31. Cooke CR, Ruiz-Maza F., Kowarski A., Migeon CJ, Walker WG Regulation of plasma aldosterone concentration in anephric man and renal transplant recipients. Kidney Int 1973 ; 3: 160-166.
32. Hene RJ, Boer P., Koomans HA, Mees EJ Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982 ; 21: 98-101.
33. Sato A., Funder JW, Saruta T. Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens 1999 ; 12: 867-873.
34. Gross E., Rothstein M., Dombek S., Juknis HI Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 2005 ; 46: 94-101.
35. Kohagura K., Higashiuesato Y., Ishiki T. et al. Plasma aldosterone in hypertensive patients on chronic hemodialysis: distribution, determinants and impact on survival. Hypertens Res 2006 ; 29: 597-604.
36. Lin YP, Yu WC, Hsu TL, Ding PY, Yang WC, Chen CH The extracellular fluid-to-intracellular fluid volume ratio is associated with large-artery structure and function in hemodialysis patients. Am J Kidney Dis 2003 ; 42: 990-999.
37. Covic A., Gusbeth-Tatomir P., Goldsmith DJ Is it time for spironolactone therapy in dialysis patients? Nephrol Dial Transplant 2006 ; 21: 854-858.
38. McLaughlin N., Gehr TW, Sica DA Aldosterone-receptor antagonism and end-stage renal disease. Curr Hypertens Rep 2004 ; 6: 327-330.
39. Saudan P., Mach F., Perneger T. et al. Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant 2003 ; 18: 2359-2363.
40. Nitta K., Akiba T., Nihei H. Aldosterone blockade and vascular calcification in hemodialysis patients. Am J Med 2003 ; 115: 250.
41. Hussain S., Dreyfus DE, Marcus RJ, Biederman RW, McGill RL Is spironolactone safe for dialysis patients? Nephrol Dial Transplant 2003 ; 18: 2364-2368.
42. Perez GO, Lespier L., Jacobi J. et al. Hyporeninemia and hypoaldosteronism in diabetes mellitus. Arch Intern Med 1977 ; 137: 852-855.
43. Krug AW, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension 2008 ; 51: 1252-1258.
44. Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A. et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 2003 ; 100: 14211-14216.